drugset / Trial / NCT04990427
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
NaSequentialOpen-labelTreatment
Summary
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
Timeline
- Start
- 2022-01-10
- Primary completion
- 2023-01-26
- Completion
- 2023-01-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells | Unknown | 1e+06 cells | Other |
| Subject | rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells | Unknown | 3e+08 cells | Other |